An interventional study of Office-based accommodative/vergence therapy and home reinforcement in Intermittent Exotropia, sponsored by Sun Yat-sen University. Status unknown. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-23.
Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment
Effectiveness of office based vergence/accommodative therapy for the treatment of intermittent exotropia is investigated through a randomized clinical trial
Purpose of study:
i) To evaluate the short-term effectiveness of office based vergence/accommodative therapy (OBVAT) for improving control of intermittent exotropia compared to observation alone; ii) To evaluate the long-term effectiveness of OBVAT for improving control of intermittent exotropia compared to observation alone; iii) To determine the natural history of intermittent exotropia among patients aged 6 to \< 18 years who have baseline near stereoacuity of 400 arc sec or better using the Preschool Randot stereotest
58 studies on the registry are indexed under Exotropia; 13 are open to participants now.
This study's planned enrollment of 40 is below the median of 50 across 49 interventional studies indexed under Exotropia.
Browse Exotropia studies →Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 619 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Control of deviation meeting all the following criteria based on the office control score scale:
4.1 Intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control ≥ Grade 2)# 4.2 Intermittent exotropia or exophoria at near (at least 1 of 3 assessments of near control at the baseline visit Grade 0-4) or orthophoria
Must be wearing the updated refractive correction (spectacles) for at least 2 weeks if refractive error (based on cycloplegic subjective refraction performed within 6 months) meets any of the following:
7.1 Myopia >-0.50 D spherical equivalent in either eye 7.2 Anisometropia >1.00 D spherical equivalent 7.3 Astigmatism in either eye >1.50 D
Refractive correction must meet the following guidelines:
8.1 Anisometropia spherical equivalent must be within 0.25 D of the full anisometropic difference 8.2 Astigmatism cylinder must be within 0.25 D of full correction and axis must be within 5 degree 8.3 For hyperopia and myopia, the spherical component can be reduced by investigator discretion provided reduction is symmetrical and results in residual (i.e., uncorrected) spherical equivalent refractive error that does not exceed +3.50 D spherical equivalent hyperopia or -0.50 D spherical equivalent myopia
Visual acuity correctable to at least 20/25 or better at distance and near in each eye.
Exclusion Criteria:
Observation only.
Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Behavioral: Office-based accommodative/vergence therapy and home reinforcement
Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Comparison of the distant office control score between two groups at the primary outcome visit
Comparison of the distant office control score between two groups at the primary outcome visit
Time frame: 16 months
Comparison of percentage of patients showing ≥ 1 point change and ≥ 2 points change in office control score
Comparison of percentage of patients showing ≥ 1 point change and ≥ 2 points change in office control score
Time frame: 16 months
Comparison of deterioration rate between 2 groups
Comparison of deterioration rate between 2 groups
Time frame: 16 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2021; primary completion for Jun 2023, 27 months later.
Of 29 interventional studies with no phase under Exotropia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.